Lantheus doses first patient in SPARROW prostate cancer imaging trial

September 28, 2026 8:00 AM

Lantheus Holdings (NASDAQ: LNTH) announced that the first patient has been dosed in SPARROW, a Phase 2/3 registrational trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found